Imugene Limited ( (AU:IMU) ) just unveiled an update.
Imugene Limited announced promising results from its Phase 1b trial of azer-cel, a CD19 CAR T therapy, in treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The trial showed a 57% complete response rate among evaluable patients, with two additional complete responses recently observed. The trial highlights azer-cel’s potential in addressing unmet needs in difficult-to-treat patient populations, especially those who have failed multiple lines of therapy, including autologous CAR T treatments. The company is actively enrolling patients across 13 US sites and up to 5 sites in Australia, with ongoing monitoring for response durability.
More about Imugene Limited
Imugene Limited is a clinical-stage immuno-oncology company that focuses on developing innovative cancer therapies. The company’s primary products include allogeneic off-the-shelf CAR T-cell therapies, with a particular market focus on treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL), a challenging type of blood cancer.
YTD Price Performance: 35.00%
Average Trading Volume: 175,002
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $173.3M
For detailed information about IMU stock, go to TipRanks’ Stock Analysis page.